Magnet Committee approves 13 projects

The Magnet Committee, under the auspices of the Office of the Chief Scientist, has approved a grant of NIS 39.2 million for the support of 13 projects under the Nofar program, dedicated to the research and development in biotechnology and nanotechnology.

By SHARON WROBEL
September 12, 2006 09:14

The Magnet Committee, under the auspices of the Office of the Chief Scientist, has approved a grant of NIS 39.2 million for the support of 13 projects under the Nofar program, dedicated to the research and development in biotechnology and nanotechnology. The Nofar program aims to advance academic research to where it is ready for a cooperative venture with a commercial or industry partner. Industry players involved in the approved projects include Teva Pharmaceuticals, Johnson & Johnson and Intel.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS